Oct 22, 2019
beam Announces Seed Round With Obvious Ventures
Oct 21, 2019
The Top Global Growth Stories Creating a $130 Billion Cannabis Opportunity
Oct 17, 2019
Verdemed, a Canadian medical cannabis company focused on doing business in Latin America, is sponsoring the second Like the Future Cannabusiness forum, organized by Lide Futuro, in São Paulo, Brazil
Oct 17, 2019
Cannabis and Compassionate Capitalism: Introducing CitizenGrown, "By the People, for the People"
Oct 16, 2019
A Global Leader in Cannabis Data & Media
Oct 16, 2019
Cannabics Pharmaceuticals Announces Publication of Clinical Data From Its Sponsored Pilot Study on Controlled Release Capsules, on the Journal of Integrative Cancer Therapies
Oct 16, 2019
Consumer Legalization One Year Later: Aurora Cannabis Reveals Sneak Peek of Plans for NextGen Cannabis Products
Oct 15, 2019
Canopy Growth completes previously announced acquisition of Beckley Canopy Therapeutics
Oct 15, 2019
Westleaf Receives Health Canada Standard Processing Licence
Oct 15, 2019
Ikänik Farms Announces 100% Acquisition of Pideka SAS, a Leading Colombian Medical Cannabis Company
Oct 10, 2019
Groundbreaking Cannabis Europa Conference Convenes in New York on November 7
Oct 10, 2019
Cultivators Manipulate Cannabis Plants to Offer Consumers Diverse Products
Oct 10, 2019
Cannafornia Announces New Division For CBD Products
Oct 09, 2019
CannabCo pioneers New Cannabis Market Segment With Exclusive Odourless Cannabis(TM) Product
Oct 09, 2019
True Farma, a medical cannabis company, brings the "Farmacy" to patients, advocates & providers.
Oct 08, 2019
Patients Forego Traditional Prescriptions in Favor of Cannabis
Oct 08, 2019
Canary RX Inc., Awarded 3 Licenses from Health Canada to Cultivate, Process and Sell Cannabis Pursuant to the Cannabis Act
Oct 07, 2019
Twisted Extracts is Proud to Announce the Upcoming Launch of Their Website
Oct 07, 2019
OWC Pharmaceutical Research Corp. to Report Top Line Results (TLR) for a Safety Study on Its Cannabis-based Tablets
Oct 07, 2019
KALY - Kali-Extracts Cannabis Extract Biopharmaceutical Developments Validate $0.05 Analyst PPS Target